Company Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins αvß8 and αvß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 158 |
| CEO | Bernard Coulie |
Contact Details
Address: 260 Littlefield Avenue South San Francisco, California 94080 United States | |
| Phone | 650 481 6770 |
| Website | pliantrx.com |
Stock Details
| Ticker Symbol | PLRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001746473 |
| CUSIP Number | 729139105 |
| ISIN Number | US7291391057 |
| Employer ID | 47-4272481 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer |
| Mike Ouimette J.D. | General Counsel and Corporate Secretary |
| Johannes P. Hull | Chief Business Officer |
| Dr. Eric A. Lefebvre M.D. | Chief Medical Officer |
| Dr. Rik Derynck | Scientific Founder and Member of Scientific Advisory Board |
| Dean Sheppard M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Bill DeGrado Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Hal Chapman M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Craig D. Muir | Interim Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |